REG - Indivior PLC - INDIVIOR MAKES STATEMENT ON COURT DECISION
RNS Number : 9478HIndivior PLC20 November 2018INDIVIOR MAKES STATEMENT ON COURT DECISION
"Indivior is disappointed that the U.S. Court of Appeals for the Federal Circuit has vacated the preliminary injunction against Dr. Reddy's Laboratories ("DRL"). Indivior will continue to vigorously pursue ongoing infringement cases against DRL to protect its SUBOXONE® (buprenorphine and naloxone) Sublingual Film patent portfolio.
The Company is in the process of interpreting the ruling in its entirety and will issue a statement on its implications once this review has been completed."
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDMSCLLFFELELIFIT
Recent news on Indivior
See all newsREG - Indivior PLC - Publication of Notice of Annual General Meeting
AnnouncementREG - Indivior PLC - Transaction in Own Shares
AnnouncementREG - Indivior PLC - Transaction in Own Shares
AnnouncementREG - Indivior PLC - Transaction in Own Shares
AnnouncementREG - Indivior PLC - Transaction in Own Shares
Announcement